Fig. 1From: An estimate of rate of deviation from NCCN guideline recommendations for central nervous system imaging in trials forming basis for drug approval in first line advanced non-small cell lung cancer (NSCLC)Flowchart of Trials Forming Basis for FDA Approval for first Line Advanced NSCLC Therapeutics from 2015 to 2020. *Two trials were both early phase and not yet publishedBack to article page